Heparin use during dialysis sessions induces an increase in the antiangiogenic factor soluble Flt1

Nephrology Dialysis Transplantation

Volumn 29, Issue 6, 2014, Pages 1225-1231

  Lavainne, Frédéric ^a,b   Meffray, Emmanuelle ^a   Pepper, Ruth J ^c   Néel, Mélanie ^a   Delcroix, Catherine ^b   Salama, Alan D ^c   Fakhouri, Fadi ^a,b  

^a INSERM   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

haemodialysis; heparin; sFlt1; VEGF

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; VASCULOTROPIN RECEPTOR 1;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; END STAGE RENAL DISEASE; ENDOTHELIUM CELL; FEMALE; HEALTH IMPACT ASSESSMENT; HEMODIAFILTRATION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEPARINIZATION; HUMAN; IN VITRO STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN SECRETION; TREATMENT RESPONSE; VERY ELDERLY; YOUNG ADULT;

HAEMODIALYSIS; HEPARIN; SFLT1; VEGF;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; HEMODIAFILTRATION; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MEMBRANES, ARTIFICIAL; MIDDLE AGED; NEOVASCULARIZATION, PHYSIOLOGIC; PREGNANCY; RENAL DIALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; YOUNG ADULT;

EID: 84901788373     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft517     Document Type: Article

References (32)

1. Himmelfarb J, Ikizler TA. Hemodialysis. N Engl J Med 2010; 363: 1833-1845
2. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998; 339: 799-805 (Pubitemid 28447453)
3. Stam F, van Guldener C, Becker A et al. Endothelial dysfunction contributes to renal function-associated cardiovascular mortality in a population with mild renal insufficiency: the Hoorn study. J Am Soc Nephrol 2006; 17: 537-545
4. Wu-Wong JR. Endothelial dysfunction and chronic kidney disease: treatment options. Curr Opin Investig Drugs 2008; 9: 970-982
5. Zoccali C, Tripepi G, Mallamaci F. Predictors of cardiovascular death in ESRD. Semin Nephrol 2005; 25: 358-362 (Pubitemid 41655967)
6. Honda H, Qureshi AR, Heimburger O et al. Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 2006; 47: 139-148 (Pubitemid 41828276)
7. Stenvinkel P, Ketteler M, Johnson RJ et al. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia-the good, the bad, and the ugly. Kidney Int 2005; 67: 1216-1233 (Pubitemid 40463099)
8. Zoccali C, Bode-Boger S, Mallamaci F et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358: 2113-2117 (Pubitemid 34094901)
9. Di Marco GS, Reuter S, Hillebrand U et al. The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD. J Am Soc Nephrol 2009; 20: 2235-2245
10. Jung JJ, Tiwari A, Inamdar SMet al. Secretion of soluble vascular endothelial growth factor receptor 1 (sVEGFR1/sFlt1) requires Arf1, Arf6, and Rab11 GTPases. PLoS One 2012; 7: e44572
11. Rahimi N, Golde TE, Meyer RD. Identification of ligand-induced proteolytic cleavage and ectodomain shedding of VEGFR-1/FLT1 in leukemic cancer cells. Cancer Res 2009; 69: 2607-2614
12. Thomas CP, Andrews JI, Liu KZ. Intronic polyadenylation signal sequences and alternate splicing generate human soluble Flt1 variants and regulate the abundance of soluble Flt1 in the placenta. Faseb J 2007; 21: 3885-3895 (Pubitemid 350232346)
13. Levine RJ, Lam C, Qian C et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355: 992-1005 (Pubitemid 44343543)
14. Girardi G, Yarilin D, Thurman JM et al. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med 2006; 203: 2165-2175 (Pubitemid 44352237)
15. Langer HF, Chung KJ, Orlova VV et al. Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis. Blood 2010; 116: 4395-4403
16. Caglar K, Peng Y, Pupim LB et al. Inflammatory signals associated with hemodialysis. Kidney Int 2002; 62: 1408-1416
17. Gamboa JL, Pretorius M, Todd-Tzanetos DR et al. Comparative effects of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on inflammation during hemodialysis. J Am Soc Nephrol 2012; 23: 334-342
18. Le Roux S, Pepper RJ, Dufay A et al. Elevated soluble Flt1 inhibits endothelial repair in PR3-ANCA-associated vasculitis. J Am Soc Nephrol 2012; 23: 155-164
19. Kodama Y, Kitta Y, Nakamura T et al. Atorvastatin increases plasma soluble Fms-like tyrosine kinase-1 and decreases vascular endothelial growth factor and placental growth factor in association with improvement of ventricular function in acute myocardial infarction. J Am Coll Cardiol 2006; 48: 43-50 (Pubitemid 43929228)
20. Ky B, French B, Ruparel K et al. The vascular marker soluble fms-like tyrosine kinase 1 is associated with disease severity and adverse outcomes in chronic heart failure. J Am Coll Cardiol 2011; 58: 386-394
21. Guo Q, Carrero JJ, Yu X et al. Associations of VEGF and its receptors sVEGFR-1 and -2 with cardiovascular disease and survival in prevalent haemodialysis patients. Nephrol Dial Transplant 2009; 24: 3468-3473
22. Liakopoulos V, Eleftheriadis T, Kyropoulos T et al. Hemodialysis procedure does not affect the levels of sICAM-1 and sVCAM-1 in patients with end stage renal disease. Ren Fail 2005; 27: 315-321 (Pubitemid 40770611)
23. Maynard SE, Min JY, Merchan J et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-658 (Pubitemid 36278583)
24. Davenport A. What are the options for anticoagulation needs in dialysis for patients with heparin-induced thrombocytopenia? Semin Dial 2011; 24: 382-385
25. Rosenberg VA, Buhimschi IA, Lockwood CJ et al. Heparin elevates circulating soluble fms-like tyrosine kinase-1 immunoreactivity in pregnant women receiving anticoagulation therapy. Circulation 2011; 124: 2543-2553
26. Searle J, Mockel M, Gwosc S et al. Heparin strongly induces soluble fmslike tyrosine kinase 1 release in vivo and in vitro-brief report. Arterioscler Thromb Vasc Biol 2011; 31: 2972-2974
27. Sela S, Natanson-Yaron S, Zcharia E et al. Local retention versus systemic release of soluble VEGF receptor-1 are mediated by heparin-binding and regulated by heparanase. Circ Res 2011; 108: 1063-1070
28. Horl WH. Hemodialysis membranes: interleukins, biocompatibility, and middle molecules. J Am Soc Nephrol 2002; 13 (Suppl 1): S62-S71
29. Panichi V, Tetta C. On-line hemodiafiltration in the large RISCAVID study. Contrib Nephrol 2011; 175: 117-128
30. Locatelli F, Manzoni C, Vigano S et al. Hemodiafiltration-state of the art. Contrib Nephrol 2011; 168: 5-18
31. Maduell F, Moreso F, Pons M et al. High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol 2013; 24: 487-497
32. Thadhani R, Kisner T, Hagmann H et al. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 2011; 124: 940-950